HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Quick Read Hims & Hers (HIMS) pulled its semaglutide pill after legal threats from Novo Nordisk and the FDA. Hims shares plunged 22%. Hims Q3 revenue jumped 49% to $599M despite regulatory pressure. Subscriber base expanded 21% to 2.5M users. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here. Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth compan ...